Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spyre TherapeuticsFRA:3920 29 14-Day RSI is 58.05 as of Aug. 09, 2026. GuruFocus rates FRA:3920 with a GF Score™ of 29/100 and a GF Value™ of €1.98 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,418 Biotechnology companies, Spyre Therapeutics ranks worse than 80.04% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Spyre Therapeutics 14-Day RSI Related Terms
FRA:3920 vs CRNX, PTGX, PRAX: 14-Day RSI Comparison
For the Biotechnology subindustry, Spyre Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics (FRA:3920) has a 14-Day RSI of 58.05 as of Aug. 09, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #1135 out of 1418 companies in the Biotechnology industry, placing it in the top 80%.
Is Spyre Therapeutics' 14-Day RSI too high?
Spyre Therapeutics' current 14-Day RSI is 58.05. The Biotechnology industry median 14-Day RSI is 51.09. Spyre Therapeutics' value of 58.05 is 13.6% above this industry median. Based on the distribution chart, Spyre Therapeutics ranks #1135 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' 14-Day RSI compare to CRNX and PTGX?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #1135 out of 1418 companies for 14-Day RSI. This places Spyre Therapeutics in the lower half of its industry. The industry median 14-Day RSI is 51.09. Spyre Therapeutics' value of 58.05 is 13.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 51.09, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spyre Therapeutics's current 14-Day RSI of 58.05 is 13.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Spyre Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 51.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current 14-Day RSI is 58.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spyre Therapeutics (FRA:3920) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.98, compared to a current price of €90.00 — trading 4445.5% above its estimated fair value. The current 14-Day RSI is 58.05 and 13.6% above the Biotechnology industry median of 51.09. Spyre Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current 14-Day RSI is 58.05 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spyre Therapeutics (FRA:3920) Overvalued in 2026?
Based on GuruFocus' analysis, Spyre Therapeutics stock appears to be overvalued.
The current stock price of €90.00 is trading 4445.5% above its estimated GF Value™ of €1.98.
GuruFocus considers Spyre Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:3920:
14-Day RSI: 58.05
GF Value™: €1.98 vs. price of €90.00 (4445.5% above fair value)
Industry Position: 13.6% above the Biotechnology median (#1135 of 1418)
No single metric tells the full story. See the FRA:3920 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
29GF Score
Get the complete analysis for FRA:3920
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3920 has been successfully added to your 
